詳細検索はこちら

南口 仁志

所属部署名輸血部
職名講師
 
 
更新日: 17/11/17 10:04

研究者基本情報

氏名

    南口 仁志

所属(マスタ)

  • 輸血部 講師

学歴

  • - 2001年 滋賀医科大学 医学系研究科 生体防御機構系
  • - 1994年 滋賀医科大学 医学部 医学科

学位

  • 医学博士(滋賀医科大学)

所属学協会

    日本リンパ網内系学会 , 日本骨髄腫学会 , 日本血栓止血学会 , 日本エイズ学会 , 日本アフェレシス学会 , 日本自己血輸血学会 , 日本内科学会 , 日本消化器病学会 , 日本消化器内視鏡学会 , 日本血液学会 , 日本造血細胞移植学会 , 米国血液学会 , 日本輸血・細胞治療学会 , 日本感染症学会 , 日本化学療法学会

委員歴

  • 日本アフェレシス学会 評議員
  • 日本造血細胞移植学会 造血細胞移植認定医
  • 日本輸血・細胞治療学会 認定医・細胞治療認定管理師
  • 日本血液学会 血液専門医
  • 日本内科学会 認定内科医・総合内科専門医

経歴

  • 2015年- 現在 滋賀医科大学医学部附属病院 輸血部(講師)
  • 2013年- 2015年 滋賀医科大学医学部附属病院 輸血部(講師(学内))
  • 2008年- 2013年 滋賀医科大学医学部附属病院 輸血部(助教)
  • 2007年- 2008年 滋賀医科大学 医学部内科学講座(助教)
  • 2005年- 2007年 滋賀医科大学 医学部内科学講座(助手)
  • 2002年- 2005年 米国サウスカロライナ医科大学 内科(Postdoctoral Fellow)
  • 2001年- 2001年 弘英会琵琶湖大橋病院 消化器科(副部長)
  • 1996年- 1999年 弘生会西京都病院 内科(医員)
  • 1994年- 1996年 滋賀医科大学附属病院 第二内科(研修医)

研究活動情報

研究分野

  • 内科系臨床医学 / 血液内科学

研究キーワード

    輸血医学 , 造血細胞移植 , 幹細胞生物学

論文

  • Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.
    Kimura SI, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Hatsumi N, Minamiguchi H, Miyatake J, Handa H, Akiyama N, Kanda Y, Yoshida M, Kiyoi H, Miyazaki Y, Naoe T, Japan Adult Leukemia Study Group (JALSG).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2017年06月 [査読有り]
  • Central nervous system involvement of acute promyelocytic leukemia, three case reports.
    Furuya A, Kawahara M, Kumode M, Ohira Y, Usui A, Nagai S, Hosoba S, Minamiguchi H, Kito K, Andoh A
    Clinical case reports 5(5) 645-653 2017年05月 [査読有り]
  • 平成26年度血液製剤使用量等アンケート調査報告
    鈴木 孝世, 大野 辰治, 内海 貴彦, 中尾 光成, 南口 仁志, 小川 雅巳, 北村 憲一, 南部 卓三, 布施 秋久, 長谷川 正人, 吉川 浩平, 亀崎 洋, 益子 進也, 小笹 宏, 角野 文彦, 滋賀県輸血療法委員会
    滋賀医学 39 33-41 2017年03月
    平成26年度輸血用血液製剤供給実績のある滋賀県内医療機関61施設を対象として実施し、55施設から回答を得た。病床規模別の回収率は、一般病床数500床以上(大規模病院)5施設で100%、一般病床数200床以上500床未満(中規模病院)8施設で89%、一般病床数200床未満(小規模病院)42施設で89%であった。輸血療法委員会は58%が設置し、病床規模別では大規模病院100%、中規模病院100%、小規模病院45%であった。輸血部門は25%(14施設)が設置していた。危機的出血時の輸血体制は、200床以上の医療機関では管理体制とガイドラインの周知、院内マニュアルの整備は約90%であり、病床数の小さい医療機関の体制整備率が低かった。病床数が多い医療機関ほど血液在庫数は多かった。1施設あたりの平均廃棄率は、新鮮凍結血漿6.2%、血小板0.1%、赤血球2.8%であった。自己血輸血は、200床以上の医療機関で全て実施され、199床以下の医療機関でも36%の実施率であった。輸血事故・副作用対策については、32施設で体制が整えられていた。
  • Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients.
    Koizumi Y, Shimizu K, Shigeta M, Okuno T, Minamiguchi H, Kito K, Hodohara K, Yamagishi Y, Andoh A, Fujiyama Y, Mikamo H
    BMC infectious diseases 17(1) 27 2017年01月 [査読有り]
  • Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases
    Yusuke Koizumi, Tomoko Uehira, Yasunori Ota, Yoshihiko Ogawa, Keishiro Yajima, Junko Tanuma, Mihoko Yotsumoto, Shotaro Hagiwara, Satoshi Ikegaya, Dai Watanabe, Hitoshi Minamiguchi, Keiko Hodohara, Kenta Murotani, Hiroshige Mikamo, Hideho Wada, Atsushi Ajisawa, Takuma Shirasaka, Hirokazu Nagai, Yoshinori Kodama, Tsunekazu Hishima, Makoto Mochizuki, Harutaka Katano, Seiji Okada
    International Journal of Hematology 104(6) 669-681 2016年12月 [査読有り]
    Plasmablastic lymphoma (PBL) is a rare AIDS-related malignancy with a poor prognosis. Little is known about this entity, and no standard treatment regimen has been defined. To establish an adequate treatment strategy, we investigated 24 cases of PBL arising in human immunodeficiency virus-positive individuals. Most of the patients were in the AIDS stage, with a median CD4 count of 67.5/µL. Lymph nodes (58 %), gastrointestinal tract (42 %), bone marrow (39 %), oral cavity (38 %), and CNS (18 %) were the most commonly involved sites. Histology findings for the following were positive at varying rates, as follows: CD10 (56 %); CD30 (39 %); CD38 (87 %); MUM-1 (91 %); CD138 (79 %); EBER (91 %); and LMP-1 (18 %). There was a marked increase in patients in 2011–12, and the cases found in that period appeared to be more aggressive, showing a higher rate of advanced-stage PBL. Fourteen cases were treated with CHOP, while the others were treated with more intensive regimens, including bortezomib and hematopoietic stem cell transplantation. The overall median survival time was 15 months. A CD4 count of >100/µL at diagnosis and attaining complete remission in the first-line chemotherapy were associated with better outcomes (P = 0.027 and 0.0016, respectively). Host immune status and chemosensitivity are associated with improved prognosis in PBL.
  • 分娩間近に診断され、分娩時大量出血を来した急性前骨髄球性白血病(APL)合併妊娠
    久保 卓郎, 井上 貴至, 小野 哲男, 四方 寛子, 喜多 伸幸, 三ツ浪 真紀子, 林 香里, 桂 大輔, 天野 創, 辻 俊一郎, 脇ノ上 史朗, 中川 哲也, 石河 顕子, 木村 文則, 高橋 健太郎, 村上 節, 浅井 愛, 南口 仁志, 木藤 克之
    滋賀医科大学雑誌 29(1) 21-26 2016年05月
    急性前骨髄球性白血病(APL)は急性骨髄性白血病全体の10〜15%を占め、治療に全トランス酸レチノイン酸(ATRA)療法が導入されて以来、その予後は改善されているが、早期に播種性血管内凝固症候群(DIC)を併発しやすい重篤な疾患である。妊娠後期にAPLと診断され、分娩までにATRA療法によってDICの改善を図る時間がなく、低フィブリノゲン血症による分娩時大量出血を来たした症例を経験した。症例は34歳、1経妊1経産、近医で妊婦健診を受けていたが、妊娠30週頃から体幹と四肢に紫斑が出現し、妊娠37週に鼻出血が1時間止まらず、健診時に汎血球減少を認め、妊娠37週6日に当院紹介受診。末梢血液検査で病的白血球の出現とDICを認め、骨髄穿刺でAPLと診断された。妊娠38週0日に自然陣痛発来し、妊娠38週1日に2978gの男児を経腟分娩したが、胎盤娩出して腟壁裂傷を縫合後、腟壁血腫による大量出血が持続した。ガーゼ圧迫で止血が得られず、分娩後2時間で出血量は3200gに達した。FFPを16単位投与してもFibrinogen値は30mg/dlと上昇せず、濃縮フィブリノゲン製剤2g投与後、手術室で全身麻酔下に再縫合とガーゼ圧迫を行い、最終的に出血が減少した。分娩後早期より血液内科でATRAおよび抗癌剤による治療が開始され、その後に完全寛解が得られた。産後5年以上が経過するが、現在のところ再発を認めていない。(著者抄録)
  • Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.
    Takebayashi K, Sonoda H, Shimizu T, Ohta H, Minamiguchi H, Ishida M, Mekata E, Endo Y, Tani T, Tani M
    World journal of surgical oncology 14 116 2016年04月 [査読有り]
    Pyomyositis is a rare, subacute, deep pyogenic infection of the muscle tissue. This disease has been previously described in patients that were immunocompromised due to a hematological malignancy. A 68-year-old man with a history of chronic myeloid leukemia was treated with imatinib. He was diagnosed with ascending colon cancer and underwent curative surgery. His postoperative course was uneventful, and he was healthy at 6 months after surgery, allowing for reinitiation of imatinib therapy. After the reinitiation of therapy, a computed tomography (CT) scan revealed a mass shadow in the right iliopsoas muscle. This lesion was clinically diagnosed as recurrent colon cancer with an abscess, which was resected surgically. A pathological examination uncovered both edema and inflammation. Two months after the second surgery, imatinib therapy was reinitiated; however, he again developed painful swelling and erythema in his right thigh. A CT scan revealed a similar shadow as described previously. He was then diagnosed with pyomyositis; he underwent incisional drainage and was administered linezolid. Following the treatment for pyomyositis, there was no cancer recurrence or evidence of any recurrent pyomyositis. Findings from this case suggest that both undergoing surgery and receiving imatinib therapy may modulate an individual's immune response, whereby the surgical site becomes more prone to infection and may predispose an individual to pyomyositis. The case report is followed by a discussion of the literature regarding this disease, including potential risk factors and the underlying pathogenesis.
  • Mycobacterium shigaense Causes Lymph Node and Cutaneous Lesions as Immune Reconstitution Syndrome in an AIDS Patient: The Third Case Report of a Novel Strain Non-tuberculous Mycobacterium.
    Koizumi Y, Shimizu K, Shigeta M, Minamiguchi H, Hodohara K, Andoh A, Tanaka T, Chikamatsu K, Mitarai S, Mikamo H
    Internal medicine (Tokyo, Japan) 55(22) 3375-3381 2016年11月 [査読有り]
    A 40-year-old man complaining of progressive body weight loss was diagnosed to have acquired immunodeficiency syndrome. Within 2 weeks after the initiation of combination antiretroviral therapy, he developed fever, massive cervical lymphadenopathy and a protruding subcutaneous abscess. A lymph node biopsy and abscess drainage revealed non-caseous granuloma and mycobacterium. The mycobacterium belonged to Runyon II group, but it showed no matches to any previously reported species. According to sequence analyses, the strain was identified as Mycobacterium shigaense. After six months of antimycobacterial treatment, the lesions were all successfully cured. This is the third case report of the novel mycobacterium, M. shigaense, presenting in associatioin with immune reconstitution syndrome.
  • Catastrophic gangrene caused by heat-insoluble cryoglobulins.
    Fujimoto N, Nakanishi G, Shirai M, Fujii N, Minamiguchi H, Hodohara K, Tanaka T
    Eur J Dermatol 21(5) 817-818 2011年09月 [査読有り]
  • Herpes folliculosebaceous ulcer in a patient with chronic lymphocytic leukaemia: An ulcerative variant of herpes folliculitis associated with herpesvirus invasion of folliculosebaceous units in immunocompromised hosts: Viewpoints in dermatology • Correspo
    N. Fujimoto, M. Wakabayashi, T. Tanaka, H. Minamiguchi, K. Hodohara
    Clinical and Experimental Dermatology 35 447-449 2010年06月 [査読有り]
  • 頻回輸血に伴う鉄過剰症患者の生化学検査値に関する知見
    湯本 浩史, 大槻 隆明, 椿野 悦子, 吉村 正幸, 吉田 孝, 南口 仁志, 程原 佳子, 岡部 英俊
    医学検査 59(5) 746-750 2010年05月 [査読有り]
    輸血後鉄過剰症患者の肝臓、心臓、膵内分泌機能に関する生化学検査値を調査した。血清フェリチン値が連続する2回の測定で1000ng/dlを超えた対象患者は11例で、再生不良性貧血6例、骨髄異形成症候群3例、白血病1例、先天性赤血球異形成貧血1例であった。直近1年間に受けた赤血球濃厚液の輸血量は、0~19単位3例、20~39単位2例、40~99単位5例、100単位以上1例であった。総赤血球濃厚液輸血量は、40~99単位7例、100単位以上4例で、平均輸血量は131.5単位であった。血清フェリチン値が5000ng/mlを超えた2例が肝酵素異常を示した。BNP検査を実施した患者は9例で、100pg/mlを超えた患者は6例であった。5例に心臓エコー検査を実施したが、左室駆出率の異常は認めなかった。血糖検査が実施されていた患者は7例で、基準値を超えた患者は5例であった。
  • Transplanted human cord blood cells generate amylase-producing pancreatic acinar cells in engrafted mice.
    Minamiguchi H, Ishikawa F, Fleming PA, Yang S, Drake CJ, Wingard JR, Ogawa M
    Pancreas 36(2) e30-e35-5 2008年03月 [査読有り]
    Pancreatic acinar cells and hepatocytes arise from the same cell population located within the embryonic endoderm. It has been reported that a multipotent population of liver cells is capable of differentiating into pancreatic cells. Recent studies revealed that murine and human hematopoietic cells could generate hepatocytes in vivo. Based on this developmental proximity between liver and pancreatic acinar cells, we examined whether human cord blood (CB) cells can generate pancreatic cells in vivo using a murine xenograft model. METHODS: We transplanted 1 x 10 CD34 human CB cells into "conditioned" newborn nonobese diabetic-severe combined immunodeficiency/beta-2 microglobulin-null mice via facial vein injection and, 3 to 4 months later, examined the pancreata from recipient mice showing high-level human multilineage hematopoietic engraftment in the bone marrow. Reverse transcriptase-polymerase chain reaction and immunohistochemical analyses revealed human amylase mRNA and protein expression, respectively, in the pancreata from recipient mice. Using fluorescence in situ hybridization, we identified human alpha-satellite, DNA-positive cells with a morphology characteristic of pancreatic acinar cells. We also identified cells in paraffin sections of the pancreata that expressed amylase mRNA, had morphological characteristics of acinar cells, and contained human but not mouse centromeric DNA. These findings establish that human umbilical CB cells are capable of generating pancreatic acinar cells via a nonfusion mechanism.
  • An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells.
    Visconti RP, Ebihara Y, LaRue AC, Fleming PA, McQuinn TC, Masuya M, Minamiguchi H, Markwald RR, Ogawa M, Drake CJ
    Circ Res 98(5) 690-696 2006年03月 [査読有り]
    Recent studies evaluating hematopoietic stem cell (HSC) potential raise the possibility that, in addition to embryonic sources, adult valve fibroblasts may be derived from HSCs. To test this hypothesis, we used methods that allow the potential of a single HSC to be evaluated in vivo. This was achieved by isolation and clonal expansion of single lineage-negative (Lin-), c-kit(+), Sca-1(+), CD34- cells from the bone marrow of mice that ubiquitously express enhanced green fluorescent protein (EGFP) combined with transplantation of individual clonal populations derived from these candidate HSCs into a lethally irradiated congenic non-EGFP mouse. Histological analyses of valve tissue from clonally engrafted recipient mice revealed the presence of numerous EGFP+ cells within host valves. A subpopulation of these cells exhibited synthetic properties characteristic of fibroblasts, as evidenced by their expression of mRNA for procollagen 1alpha1. Further, we show by Y-chromosome-specific fluorescence in situ hybridization analysis of female-to-male transplanted mice that the EGFP+ valve cells are the result of HSC-derived cell differentiation and not the fusion of EGFP+ donor cells with host somatic cells. Together, these findings demonstrate HSC contribution to the adult valve fibroblast population.
  • Hematopoietic origins of fibroblasts: I. In vivo studies of fibroblasts associated with solid tumors.
    LaRue AC, Masuya M, Ebihara Y, Fleming PA, Visconti RP, Minamiguchi H, Ogawa M, Drake CJ
    Exp Hematol 34(2) 208-218 2006年02月 [査読有り]
    Recent studies have reported that bone marrow cells can give rise to tissue fibroblasts. However, the bone marrow cell(s) that gives rise to fibroblasts has not yet been identified. In the present study, we tested the hypothesis that tissue fibroblasts are derived from hematopoietic stem cells (HSCs) in vivo. These studies were conducted using mice whose hematopoiesis had been reconstituted by transplantation of a clonal population of cells derived from a single enhanced green fluorescent protein (EGFP)-positive HSC in conjunction with murine tumor models. When tumors propagated in the transplanted mice were evaluated for the presence of EGFP(+) HSC-derived cells, two prominent populations of EGFP(+) cells were found. The first were determined to be fibroblasts within the tumor stromal capsule, a subset of which expressed type I collagen mRNA and alpha-smooth muscle actin. The second population was a perivascular cell associated with the CD31(+) tumor blood vessels. These in vivo findings establish an HSC origin of fibroblasts.
  • Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes.
    Ebihara Y, Masuya M, Larue AC, Fleming PA, Visconti RP, Minamiguchi H, Drake CJ, Ogawa M
    Exp Hematol 34(2) 219-229 2006年02月 [査読有り]
    Using transplantation of a clonal population of cells derived from a single hematopoietic stem cell (HSC) of transgenic enhanced green fluorescent protein (EGFP) mice, we have documented the hematopoietic origin of myofibroblasts, such as kidney mesangial cells and brain microglial cells. Because myofibroblasts are thought to be an activated form of fibroblasts, we tested the hypothesis that fibroblasts are derived from HSCs. Clones of cells derived from single cells of EGFP Ly-5.2 C57Bl/6 mice were transplanted into lethally irradiated Ly-5.1 mice. Using bone marrow and peripheral blood cells from mice showing high-level multilineage hematopoietic reconstitution, we induced growth of fibroblasts in vitro. Culture of EGFP(+) bone marrow cells from clonally engrafted mice revealed adherent cells with morphology typical of fibroblasts. Flow cytometric analysis revealed that the majority of these cells are CD45(-) and express collagen-I and the collagen receptor, discoidin domain receptor 2 (DDR2). Reverse transcriptase polymerase chain reaction analysis of cultured cells demonstrated expression of procollagen 1-alpha1, DDR2, fibronectin, and vimentin mRNA. Fibroblast colonies consisting of EGFP(+) cells were observed in cultures of bone marrow cells from clonally engrafted mice, indicating an HSC origin of fibroblast colony-forming units. Culture of peripheral blood nucleated cells from clonally engrafted mice revealed EGFP(+) cells expressing collagen-I and DDR2, indicating that fibrocytes are also derived from HSCs. We conclude that a population of fibroblasts and their precursors are derived from HSCs.
  • Contribution of bone marrow hematopoietic stem cells to adult mouse inner ear: mesenchymal cells and fibrocytes.
    Lang H, Ebihara Y, Schmiedt RA, Minamiguchi H, Zhou D, Smythe N, Liu L, Ogawa M, Schulte BA
    J Comp Neurol 496(2) 187-201 2006年05月 [査読有り]
    Bone marrow (BM)-derived stem cells have shown plasticity with a capacity to differentiate into a variety of specialized cells. To test the hypothesis that some cells in the inner ear are derived from BM, we transplanted either isolated whole BM cells or clonally expanded hematopoietic stem cells (HSCs) prepared from transgenic mice expressing enhanced green fluorescent protein (EGFP) into irradiated adult mice. Isolated GFP(+) BM cells were also transplanted into conditioned newborn mice derived from pregnant mice injected with busulfan (which ablates HSCs in the newborns). Quantification of GFP(+) cells was performed 3-20 months after transplant. GFP(+) cells were found in the inner ear with all transplant conditions. They were most abundant within the spiral ligament but were also found in other locations normally occupied by fibrocytes and mesenchymal cells. No GFP(+) neurons or hair cells were observed in inner ears of transplanted mice. Dual immunofluorescence assays demonstrated that most of the GFP(+) cells were negative for CD45, a macrophage and hematopoietic cell marker. A portion of the GFP(+) cells in the spiral ligament expressed immunoreactive Na, K-ATPase, or the Na-K-Cl transporter (NKCC), proteins used as markers for specialized ion transport fibrocytes. Phenotypic studies indicated that the GFP(+) cells did not arise from fusion of donor cells with endogenous cells. This study provides the first evidence for the origin of inner ear cells from BM and more specifically from HSCs. The results suggest that mesenchymal cells, including fibrocytes in the adult inner ear, may be derived continuously from HSCs.
  • An assay for human hematopoietic stem cells based on transplantation into nonobese diabetic recombination activating gene-null perforin-null mice.
    Minamiguchi H, Wingard JR, Laver JH, Mainali ES, Shultz LD, Ogawa M
    Biol Blood Marrow Transplant 11(7) 487-494 2005年07月 [査読有り]
    Nonobese diabetic recombination activating gene-null perforin-null (NOD- Rag1 null Prf1 null ) mice, which totally lack mature T and B cells and natural killer cell cytotoxic function, survive longer and are easier to breed than NOD-severe combined immunodeficiency ( scid ) or NOD- scid /beta 2 -microglobulin null mice. We have tested the use of NOD- Rag1 null Prf1 null mice as recipients in a long-term xenograft assay for human hematopoietic stem cells (HSCs) by adopting Yoder and colleagues' method of conditioned newborn mice, with minor modifications. Pregnant NOD- Rag1 null Prf1 null dams were treated with busulfan 22.5 mg/kg. On the day of delivery, the busulfan-exposed pups underwent transplantation with 4 to 5 million T cell--depleted human cord blood mononuclear cells via the facial vein. At 2 months after transplantation, all 11 transplanted mice showed human hematopoietic engraftment in the peripheral blood. At 6 months after transplantation, human cells were detected in 5 mice, which showed higher than 0.9% human cell engraftment at 2 months. The mean percentage of human CD45 + cells in the bone marrow of engrafted mice was 43.9% +/- 36.5% (range, 2.0%-79.9%). Next, we tested the usefulness of conditioned newborn NOD- Rag1 null Prf1 null mice for applications to characterize the dye efflux capability and phenotypic features of human HSCs. Given that cord blood HSCs have the ability to efflux rhodamine 123 (Rho), we attempted transplantations of sorted cells that retained a low level (Rho low ) or high level (Rho high ) of Rho. Six-month engraftment was found only with the Rho low cells, which contained high percentages of CD34 + CD38 - cells and side population cells with Hoechst 33324 efflux activity. These observations suggest that Rho low cells are highly enriched for primitive hematopoietic cells. Accordingly, conditioned newborn NOD- Rag1 null Prf1 null mice provide a desirable model for an assay of long-term transplantable human HSCs.
  • Granulocyte/macrophage origin of glomerular mesangial cells.
    Abe T, Fleming PA, Masuya M, Minamiguchi H, Ebihara Y, Drake CJ, Ogawaa M
    Int J Hematol 82(2) 115-118 2005年08月 [査読有り]
    We previously demonstrated the ability of hematopoietic stem cells (HSCs) to generate glomerular mesangial cells by trans-planting clonal populations of cells derived from a single enhanced green fluorescent protein (EGFP)-positive HSC into lethally irradiated mice. To define more precisely the hematopoietic differentiation pathway through which mesangial cells are derived, we studied the relationship between mesangial cell expression and individual hematopoietic lineages by means of a transplantation strategy. In a series of clonal HSC transplantation experiments, we generated 3 mice engrafted predominantly by granulocytes and macrophages (GMs) and 4 mice engrafted with B-cells or with B-cells and T-cells. When the kidneys of these mice were analyzed, the mice exhibiting high GM lineage engraftment revealed much higher levels of EGFP-positive mesangial cells than those with predominantly lymphocyte engraftment. Fluorescence in situ hybridization analysis of the kidneys from a male recipient of an EGFP-positive female donor excluded cell fusion as the cause for the observed differentiation. These results support the notion that glomerular mesangial cells share their origin with GMs.
  • Impaired stem cell function of CD34+ cells selected by two different immunomagnetic beads systems.
    Kimura T, Minamiguchi H, Wang J, Kaneko H, Nakagawa H, Fujii H, Sonoda Y
    Leukemia 18(3) 566-574 2004年03月 [査読有り]
    We have been investigating the hematopoietic stem cell (HSC) activity of peripheral blood-derived CD34(+) cells selected by two different laboratory immunomagnetic beads systems (MiniMACS and Isolex 50). In this study, the quality of purified CD34(+) cells was directly compared using clonal cell culture, a cobblestone area-forming cell (CAFC) assay, and an in vivo severe combined immunodeficiency (SCID)-repopulating cell (SRC) assay. It was found that CD34(+) cells selected by these two immunomagnetic methods showed a reduced yield of colony-forming cells and CAFCs compared with cells enriched by the StemSep device (a negative selection method). However, these CD34(+) cells still showed significant SRC activity, including multilineage lymphomyeloid reconstitution. The percentage of human CD45(+) cells in murine bone marrow after transplanting 5 x 10(5) CD34(+) cells selected by the Isolex 50 was significantly lower than after transplanting cells selected by the MiniMACS or the StemSep. Our findings clearly demonstrated that CD34(+) cells selected by the MiniMACS system had superior HSC functions, including SRC activity, compared with cells separated by the Isolex 50 system. More detailed functional analysis of immunomagnetically separated CD34(+) cells may provide useful knowledge for basic research on HSCs as well as for clinical HSC transplantation.
  • Human cord blood long-term engrafting cells are CD34+ CD38-.
    Ishikawa F, Livingston AG, Minamiguchi H, Wingard JR, Ogawa M
    Leukemia 17(5) 960-964 2003年05月 [査読有り]
    There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/beta2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34(+) population. The capability of secondary reconstitution was found only in the CD34(+) cells. When the CD34(+) CB cells were separated into CD38(-) and CD38(+) subpopulations and tested for engraftment, the majority of the engrafting cells were detected in the CD38(-) subpopulation. These findings are consistent with the results from studies of murine stem cells and strongly indicate that the phenotype of human CB stem cells is CD34(+) CD38(-).
  • Transplanted human cord blood cells give rise to hepatocytes in engrafted mice.
    Ishikawa F, Drake CJ, Yang S, Fleming P, Minamiguchi H, Visconti RP, Crosby CV, Argraves WS, Harada M, Key LL Jr, Livingston AG, Wingard JR, Ogawa M
    Ann N Y Acad Sci 996 174-185 2003年05月 [査読有り]
    Recent studies suggest that rodent hepatocytes may be derived from hematopoietic stem cells. In the current study, the potential hematopoietic origin of hepatocytes was addressed using xenogeneic transplantation of human cord blood cells. CD34(+) or CD45(+) human cord blood cells were transplanted into "conditioned" newborn NOD/SCID/beta2-microglobulin(null) mice. At 4 to 5 months post-transplantation, livers of the recipient mice were cryosectioned and examined for evidence of human hepatocyte engraftment using RT-PCR to detect human albumin mRNA, immunohistochemistry to detect human hepatocytic proteins, and fluorescence in situ hybridization (FISH) to detect the presence of human centromeric DNA. Analysis of the bone marrow of transplanted mice revealed that 21.0-45.9% of the cells were human CD45(+) cells. FISH analysis of frozen sections of transplanted mouse liver revealed the presence of engrafted cells positive for human centromeric DNA. That engrafted human cells functioned as hepatocytes was indicated by the expression of human albumin mRNA, as judged by RT-PCR. FISH analysis with human and mouse centromeric DNA probes excluded spontaneous cell fusion as the cause for the generation of human hepatocytes. Human cord blood cells can give rise to hepatocytes in a xenogeneic transplantation model. This model will be useful to further characterize the cord blood progenitors of hepatocytes.
  • Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
    Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, Masuda T, Kim EH, Tsuboi A, Oka Y, Soma T, Ogawa H, Sugiyama H
    Br J Haematol 116(2) 409-420 2002年02月 [査読有り]
    The Wilms' tumour gene, WT1, is expressed at high levels in leukaemia cells and plays an important role in leukaemogenesis. WT1 is also expressed in human normal CD34+ bone marrow (BM) cells at about 100 times lower levels than in leukaemia cells. To identify and characterize WT1-expressing cells in CD34+ BM cells, they were sorted into single cells and analysed for WT1 expression using two kinds of single-cell reverse transcriptase polymerase chain reaction (RT-PCR) methods. Using the semiquantitative single-cell polyA-PCR + sequence-specific (SS)-PCR method, WT1 expression was detected in four (1.3%) out of 319 CD34+ BM single cells. To confirm the above results, a single-cell nested sequence-specific (NSS)-RT-PCR method that was less quantitative but more sensitive than the polyA-PCR + SS-PCR method was also performed, and WT1 expression was detected in 15 (1.1%) out of 1315 CD34+ BM single cells. In total, WT1 expression was found in 19 (1.2%) out of 1634 CD34+ BM single cells. No significant differences in the frequencies of WT1-expressing cells were found between CD34+CD38- and CD34+CD38+ BM single cells. Furthermore, WT1-expressing CD34+ BM single cells expressed WT1 at levels similar to those in K562 leukaemia single cells. Analysis of lineage-specific and cell cycle gene expression in WT1-expressing CD34+ BM single cells showed that the WT1 gene could be expressed in both uncommitted, dormant CD34+CD38- and lineage-committed, proliferating CD34+CD38+ BM cells. Our results could indicate that these WT1-expressing CD34+ BM cells were normal counterparts of leukaemia cells.
  • Role of human interleukin-9 as a megakaryocyte potentiator in culture.
    Fujiki H, Kimura T, Minamiguchi H, Harada S, Wang J, Nakao M, Yokota S, Urata Y, Ueda Y, Yamagishi H, Sonoda Y
    Exp Hematol 30(12) 1373-1380 2002年12月 [査読有り]
    This study investigated the effect of interleukin-9 (IL-9) on the proliferation and differentiation of human colony-forming unit megakaryocytic progenitor cells (CFU-Meg). Peripheral blood-derived CD34(+)IL-6R(-) cells were sorted and cultured in the presence of IL-9, erythropoietin (Epo), stem cell factor (SCF), and thrombopoietin (TPO) alone or in combination. The number of pure and mixed megakaryocyte colonies, the size of pure megakaryocyte colonies, the ploidy distribution of megakaryocytes, and proplatelet formation were investigated. Apart from TPO, no single factor could support CFU-Meg-derived colony formation, but each two-factor combination among IL-9, Epo, and SCF supported a few CFU-Meg colonies. Interestingly, the combination of Epo+SCF+IL-9 induced four to six times as many CFU-Meg colonies as any of the two-factor combinations. Neutralizing monoclonal antibodies (mAbs) for IL-9 receptor and c-kit completely abolished this synergistic effect. In contrast, addition of neutralizing anti-c-Mpl or anti-CXCR4 Abs did not influence colony formation, indicating that this synergistic effect was independent of TPO or SDF-1. Moreover, the endogenous production of TPO by cultured CD34(+)IL-6R(-) cells in the presence of Epo+SCF+IL-9 was ruled out by reverse transcriptase polymerase chain reaction for TPO mRNA. Interestingly, the combination of TPO, Epo, SCF, and IL-9 supported the largest number of pure and mixed megakaryocyte colonies, suggesting that this combination of cytokines might recruit primitive megakaryocytic as well as multipotential progenitors. This combination also potently enhanced proplatelet formation compared with TPO alone or a combination of Epo, SCF, and IL-9. This study demonstrated for the first time that human IL-9 can potentiate human megakaryocytopoiesis in the presence of Epo and/or SCF.
  • Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC and MAPK pathways.
    Minamiguchi H, Kimura T, Urata Y, Miyazaki H, Bamba T, Abe T, Sonoda Y
    Br J Haematol 115(1) 175-185 2001年10月 [査読有り]
    We assessed the effect of signalling through CXCR4 on the proliferation and differentiation of human megakaryocytic progenitor cells (CFU-Meg) in the presence or absence of stem cell factor (SCF) and/or thrombopoietin (TPO), using peripheral blood-derived CD34(+)IL-6R(-) cells as a target. TPO alone induced a significant number of CFU-Meg colonies. Although stromal cell-derived factor-1 (SDF-1) or SCF alone did not support CFU-Meg colony formation, these factors had a synergistic effect on CFU-Meg colony formation in the presence of TPO. The combination of SDF-1, SCF and TPO induced twice as many CFU-Meg colonies as TPO alone. To investigate the mechanism of this synergistic action, we examined the effects of various protein kinase inhibitors on CFU-Meg colony formation. LY294002 and GF109203X (inhibitors of PI3-K and PKC respectively) completely or partially inhibited this synergistic action. In contrast, a MEK inhibitor (PD98059) did not inhibit CFU-Meg colony formation. It significantly increased the higher ploidy classes (16N to 64N) of megakaryocytes supported by TPO, TPO + SCF, TPO + SDF-1, and TPO + SCF + SDF-1, whereas it abolished the effect of SDF-1 on the increase of higher ploidy classes of megakaryocytes supported by TPO. These results suggest that MAPK may negatively or positively regulate the nuclear maturation of megakaryocytes, known as endomitosis. In the presence of PD98059, proplatelet formation (PPF) was significantly augmented, suggesting that the MAPK pathway may also inhibit the initiation of PPF. In conclusion, simultaneous activation of three signals through c-mpl, c-kit and CXCR4 can induce the in vitro proliferation and differentiation of CFU-Meg, and SDF-1 is a potentiator of human megakaryocytopoiesis.
  • Interleukin 6 receptor expression by human cord blood-or peripheral blood-derived primitive haematopoietic progenitors implies acquisition of different functional properties.
    Minamiguchi H, Yahata N, Kimura T, Fujiki H, Harada S, Wang J, Okuda K, Kaneko H, Hodohara K, Banba T, Yasukawa K, Ohyashiki JH, Ohyashiki K, Abe T, Sonoda Y
    British J. Haematology 110(2) 327-338 2000年08月 [査読有り]
    The significance of interleukin 6 receptor (IL-6R) expression by cord blood (CB)- and peripheral blood (PB)-derived primitive haematopoietic progenitors was investigated. IL-6R was preferentially expressed by PB-derived myeloid progenitors. Most PB-derived erythroid bursts (BFU-E) and mixed colony-forming cells (CFU-Mix) did not express this receptor. However, CB-derived primitive progenitor cells possessed multipotentiality, irrespective of IL-6R expression. Interestingly, the long-term culture-initiating cell (LTC-IC) population was enriched in PB-derived CD34+ IL-6R+ cells, but the extended LTC-IC (ELTC-IC) population, which represents a less mature class of haematopoietic progenitors, seemed to be equally distributed in the IL-6R+ and IL-6R- cell populations. In contrast, the number of LTC-ICs and ELTC-ICs was similar in CB-derived CD34+ IL-6R+ or IL-6R- cells. It is noteworthy that the number of LTC-ICs and ELTC-ICs in CB-derived CD34+ cells was markedly higher than that in PB-derived CD34+ cells regardless of IL-6R expression. Telomerase activity was consistently lower in PB-derived CD34+ IL-6R- cells than in CD34+ IL-6R+ cells. In contrast, telomerase activity was similar in CB-derived CD34+ IL-6R+ or IL-6R- cells. The pattern of telomerase induction upon cytokine stimulation differed between CB- and PB-derived CD34+ IL-6R+ or IL-6R- cells. However, overall telomerase activity per dish was well correlated with the proliferative potential of both cell populations, suggesting that induction of telomerase plays an important role in the escape from replicative senescence of primitive haematopoietic progenitors. Collectively, these results suggest that CB-derived primitive progenitors are less mature than PB-derived progenitors and that the expression of IL-6R by primitive haematopoietic progenitors may have different implications for PB- and CB-derived CD34+ cells.
  • Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
    Kimura T, Wang J, Minamiguchi H, Fujiki H, Harada S, Okuda K, Kaneko H, Yokota S, Yasukawa K, Abe T, Sonoda Y
    Stem Cells 18(6) 444-452 2000年 [査読有り]
    This study was designed to investigate the effects of a combination of soluble interleukin (sIL)-6 receptor (R) and IL-6 on the ex vivo expansion of human peripheral blood (PB)-derived hematopoietic progenitor cells in a short-term serum-free liquid suspension culture system, using PB-derived CD34(+)IL-6R(+/-) cells as a target. In combination with stem cell factor (SCF), IL-3, and sIL-6R/IL-6, the expansion efficiency (EE) for granulocyte/macrophage colony-forming unit (CFU-GM) reached a peak level on day 10 of incubation. On the other hand, the EE for erythroid burst (BFU-E) and mixed colony-forming unit (CFU-Mix) reached a peak level on day 7 of incubation. Among the cytokine combinations tested, SCF + IL-3 + sIL-6R/IL-6 + flt3 ligand (FL) most effectively expanded CFU-GM and CFU-Mix. The maximum EEs for CFU-GM and CFU-Mix were 208-fold and 42-fold, respectively. While the EE for BFU-E was 70-90-fold in the presence of SCF + IL-3 + sIL-6R/IL-6, FL significantly augmented the EE for CFU-GM and CFU-Mix. In contrast, thrombopoietin (TPO) significantly augmented the EE for CFU-Mix. Interestingly, in combination with IL-3 and SCF, newly generated IL-6R/IL-6 fusion protein (FP) expanded PB-derived BFU-E and CFU-Mix twice more effectively than a combination of sIL-6R and IL-6. These results demonstrated that human PB-derived committed progenitors were effectively expanded in vitro using sIL-6R/IL-6 or FP, in combination with IL-3, SCF and/or FL or TPO, and that FP may transduce a stronger intracellular signal than a combination of sIL-6R and IL-6.
  • Interleukin-11(IL-11) enhances clonal proliferation of acute myelogenous leukemia cells with strong expression of the IL-11 receptor alpha chain and signal transducing gp130.
    Kimura T, Sakabe H, Minamiguchi H, Fujiki H, Abe T, Kaneko H, Yokota S, Nakagawa H, Fujii H, Tamaki H, Ogawa H, Sugiyama H, Sonoda Y
    Leukemia 13(7) 1018-1027 1999年07月 [査読有り]
    We examined the effect of recombinant human interleukin (IL)-11 alone or in combination with various colony-stimulating factors (CSFs), including IL-3, granulocyte/macrophage (GM)-CSF, granulocyte (G)-CSF, stem cell factor (SCF), flt3 ligand (FL), and thrombopoietin (TPO), on colony formation by leukemic progenitor cells (L-CFU) obtained from 33 patients with acute myelogenous leukemia (AML). Leukemic colony formation was found in approximately 70 to 80% of the patients in the presence of at least one of the above CSFs. Although IL-11 alone did not support L-CFU, the growth of these progenitors in the presence of other cytokines was enhanced by IL-11 in 16 out of 33 patients and it showed a synergistic action with G-CSF in 12 of them. This synergistic action occurred in seven out of nine M5 patients (French-American-British (FAB) classification). A single cell clone-sorting experiment clearly demonstrated that this synergistic effect was operative at the single progenitor cell level. The number of leukemic cells proliferating in the presence of G-CSF+IL-11 was significantly higher than in the presence of G-CSF alone, suggesting that IL-11 recruited dormant leukemic progenitors into the cell cycle. Flow cytometric analysis revealed that all types of AML blast cells (M0 approximately M6) ubiquitously expressed gp130, although the level of expression was significantly higher in M5 cells. In contrast, expression of the IL-11 receptor alpha chain (IL-11Ralpha) varied between FAB types. Blast cells obtained from M1, M3 and M5 patients showed higher levels of expression, with M5 cells showing the strongest expression. Interestingly, the leukemic progenitor cells for which proliferation was synergistically enhanced by IL-11 had significantly higher expression of both IL-11Ralpha and gp130. These results suggest that administration of IL-11 in vivo may stimulate the proliferation of leukemic progenitor cells, particularly M5 cells, in the presence of G-CSF, and that the responsiveness of L-CFU to IL-11 may be predicted by a simple receptor assay.
  • Human cord blood-derived primitive progenitors are enriched in CD34+c-kit- cells: correlation between long-term culture-initiating cells and telomerase expression.
    Sakabe H, Yahata N, Kimura T, Zeng ZZ, Minamiguchi H, Kaneko H, Mori KJ, Ohyashiki K, Ohyashiki JH, Toyama K, Abe T, Sonoda Y
    Leukemia 12(5) 728-734 1998年05月 [査読有り]
    We studied the functional characteristics of subpopulations of cord blood-derived CD34+ cells expressing different levels of CD38 and c-kit antigens, using clonal cell culture and long-term culture with allogeneic bone marrow stromal cells or the MS-5 murine stromal cell line to assay long-term culture-initiating cells (LTC-IC) in each subpopulation. To investigate the capacity for replication, proliferation, and differentiation of each subpopulation of CD34+ cells, we also studied the correlation between LTC-IC and telomerase activity. After 5 weeks of coculture, LTC-IC accounted for one out of 32 CD34+CD38- cells and one out of 33 CD34+c-kit- cells. In contrast, the frequency of LTC-IC was low in their antigen-positive counterparts (one per 84 CD34+CD38+ cells, one per 90 CD34+c-kit(low) cells, and very low among CD34+c-kit(high) cells). It was noteworthy that some LTC-IC derived from CD34+CD38- as well as CD34+c-kit- cells generated colony-forming cells (CFCs) after up to 9 weeks of coculture. Telomerase activity was consistently low in CD34+CD38- and CD34+c-kit- cells compared to CD38+ or c-kit(high or low) cells, suggesting that CD34+CD38- or c-kit- cells are likely to be more quiescent. These results suggest that the CD34+CD38- and CD34+c-kit- cell populations are primitive stem/progenitor cells, and that the telomerase activity of these cells correlates with their proliferative capacity as well as their stage of differentiation.
  • Haematopoietic action of flt3 ligand on cord blood-derived CD34-positive cells expressing different levels of flt3 or c-kit tyrosine kinase receptor: comparison with stem cell factor.
    Sakabe H, Kimura T, Zeng Z, Minamiguchi H, Tsuda S, Yokota S, Hodohara K, Abe T, Lyman SD, Sonoda Y
    Eoropean Journal of Haematology 60(5) 297-306 1998年05月 [査読有り]
    We compared the effect of human flt3 ligand (FL) and stem cell factor (SCF) on cord blood (CB)-derived CD34+ cells expressing different levels of flt3 or c-kit tyrosine kinase (TK) receptor in clonal cell culture. The c-kit receptor was expressed by 58.5+/-16.7% of CB CD34+ cells (n=19), in which c-kit(high), c-kit(low) and c-kit cell populations could be identified. In contrast, the flt3 receptor (FR) was weakly expressed on 58.6+/-8.3% (n=9) of CB CD34+ cells. FL+erythropoietin (Epo) failed to support erythroid burst (BFU-E) formation by any subpopulation of CD34+ cells. However, SCF + Epo supported BFU-E and erythrocyte-containing mixed (CFU-mix) colony formation from all subpopulations. Interestingly, FL markedly augmented CFU-mix colony formation supported by interleukin (IL)-3 + Epo when CD34+c-kit(low) or CD34+FR+ cells were used as the target. On the other hand, SCF significantly enhanced CFU-mix colony formation supported by IL-3 + Epo when CD34+c-kit(high) or low and CD34+FR+ cells were used. The replating potential of CFU-mix supported by IL-3 + Epo+ FL was greater when CD34+c-kit(low) or CD34+FR+ cells were used. When the CD34+c-kit(low) cells were used, the number of lineages expressed in secondary cultures of CFU-mix colonies derived from primary cultures containing IL-3 + Epo + FL or SCF was significantly larger than when the primary cultures contained IL-3 + Epo. Furthermore, the number of long-term culture-initiating cells found in CD34+FR+ cells was larger than that in FR cells. CB-derived CD34+c-kit(low) cells represent a less mature population than c-kit(high) cells, as reported previously. Therefore, these results indicate that both FL and SCF can act on primitive multipotential progenitors. However, it is still uncertain whether CB-derived CD34+FR+ cells are less mature than CD34+FR- cells.
  • A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis.
    Nakamura F, Andoh A, Minamiguchi H, Hodohara K, Fujiyama Y, Bamba T
    Acta haematologica 97(4) 222-224 1997年02月 [査読有り]
    A 55-year-old man with myelofibrosis was treated with natural alpha-interferon with a good hematologic response. Initially, he had anemia, leukocytosis, thrombocytosis and hepatospleomegaly. A bone marrow biopsy showed replacement with fibrosis with an increase in megakaryocytes. Natural alpha-interferon (alpha-IFN) was started at a dose of 3 x 10(6) units/day. The leukocyte and platelet counts gradually normalized, and the liver and spleen decreased in size. However, the patient complained of a dry cough and dyspnea on the 61st treatment day, when the accumulated dose of alpha-IFN treatment had reached 1.8 x 10(8) units. He subsequently developed acute respiratory failure (PaO2 < 60 mm Hg) with bilateral lung infiltrations, suggesting the occurrence of interstitial pneumonitis associated with alpha-interferon therapy. Immediately, the alpha-interferon was discontinued and high-dose methylprednisolone (1.5 g/day) was administered for 3 days. This treatment was followed by oral prednisone therapy. Steroid therapy brought about gradual improvement as suggested by a repeat radiograph. Since high levels of fibrogenic cytokines, such as PDGF and TGF-beta, have been reported in patients with myelofibrosis, it is necessary to pay attention to interstitial pneumonia as a complication in alpha-IFN therapy for myelofibrosis.

講演・口頭発表等

  • 当院で経験したメソトレキセート関連リンパ増殖性疾患
    久保田 浩之, 細羽 桜, 臼井 亜沙子, 口分田 美奈, 永井 詩穂, 古屋 彩, 瀬川 秀和, 河原 真大, 南口 仁志, 木藤 克之, 安藤 朗
    滋賀医学 2017年03月
  • 当院で経験したメソトレキセート関連リンパ増殖性疾患の13例
    高原 亜弥, 細羽 桜, 臼井 亜沙子, 口分田 美奈, 永井 詩穂, 岩佐 磨佐紀, 古屋 彩, 瀬川 秀和, 河原 真大, 南口 仁志, 木藤 克之, 安藤 朗
    臨床血液 2017年01月
  • 繰り返す脳梗塞で発症し、脳生検にて診断された血管内リンパ腫の1例
    松尾 宏俊, 尾原 知行, 孫 明子, 中島 正之, 南口 仁志, 松井 宏樹, 横井 俊浩, 野崎 和彦, 水野 敏樹
    臨床神経学 2016年11月
  • 同種移植後再発および中枢神経再発に対してgemtuzumab ozogamicin併用MEC療法が有効であった急性前骨髄性白血病の1例
    永井 詩穂, 口分田 美奈, 臼井 亜沙子, 大平 泰之, 細羽 桜, 古屋 彩, 瀬川 秀和, 河原 真大, 南口 仁志, 木藤 克之, 安藤 朗
    臨床血液 2016年11月
  • 血液内科におけるCHOP療法施行時のアプレピタント使用に関する検討
    若杉 吉宣, 生野 芳博, 堀江 美弥, 木藤 克之, 南口 仁志, 寺田 智祐
    日本癌治療学会学術集会抄録集 2016年10月
  • タクロリムスの経口投与により血中濃度が100ng/mlを超える異常高値を示した症例とその考察
    磯野 哲一郎, 平 大樹, 赤羽 理也, 池田 義人, 若杉 吉宣, 永井 詩穂, 南口 仁志, 森田 真也, 木藤 克之, 寺田 智祐
    TDM研究 2016年05月
  • 急性リンパ性白血病の化学療法中に生じたRothia mucilaginosa菌血症の1例
    茶谷 元晴, 小泉 祐介, 南口 仁志, 木藤 克之
    感染症学雑誌 2016年03月
  • 脳原発悪性リンパ腫治療後、8年の経過の後に原因不明の意識障害を来したAIDS症例
    岡本 寛樹, 大平 泰之, 口分田 美奈, 臼井 亜沙子, 永井 詩穂, 古屋 彩, 瀬川 秀和, 南口 仁志, 木藤 克之, 安藤 朗
    滋賀医学 2016年03月
  • 重度腎障害/骨髄抑制を有する同種移植症例患者に認めたCMV感染とHHV-6脳症合併例 ガンシクロビルかホスカルネットか
    小泉 祐介, 南口 仁志, 藤山 佳秀, 西山 直哉, 平井 潤, 山岸 由佳, 三鴨 廣繁, 奥野 貴史
    日本化学療法学会雑誌 2016年03月
  • TTP様病態を呈した高齢者ヒトパルボウイルスB19初感染の1例
    大槻 晋士, 伊藤 千尋, 口分田 美奈, 臼井 亜沙子, 大平 泰之, 永井 詩穂, 古屋 彩, 南口 仁志, 木藤 克之, 安藤 朗
    臨床血液 2016年02月
  • 最近当院で経験した後天性血友病Aの4症例
    臼井 亜沙子, 大平 泰之, 口分田 美奈, 永井 詩穂, 古屋 彩, 南口 仁志, 木藤 克之, 安藤 朗
    臨床血液 2016年02月
  • 滋賀県中核拠点病院HIVチーム 実績と課題の報告
    美濃 亜朱, 井手 径子, 小池 ゆかり, 原田 利恵, 朝香 彩葉, 澤村 由莉, 椛島 雪, 中村 和希, 佐藤根 美愛, 美濃 正臣, 木藤 克之, 小泉 祐介, 南口 仁志, 新居 加菜
    日本エイズ学会誌 2015年11月
  • IgG4関連疾患に伴う冠動脈瘤を併発した冠動脈3枝病変に対する手術の一例
    宮下 史寛, 森本 政憲, 藤野 晋, 坂倉 玲欧, 木下 武, 乃田 浩光, 鈴木 友彰, 浅井 徹, 永谷 幸裕, 石田 光明, 南口 仁志
    日本冠疾患学会雑誌 2015年11月
  • 中枢神経再発に対して亜ヒ酸と髄注化学療法が奏効した急性前骨髄性白血病の1例
    口分田 美奈, 臼井 亜沙子, 永井 詩穂, 大平 泰之, 古屋 彩, 瀬川 秀和, 南口 仁志, 木藤 克之, 程原 佳子, 安藤 朗
    臨床血液 2015年11月
  • 発熱性好中球減少症に続発したBacillus cereus髄膜脳炎の1例
    小泉 祐介, 奥野 貴史, 南口 仁志, 藤山 佳秀
    感染症学雑誌 2015年03月
  • 胸膜肥厚を契機に発見されたIgG4関連疾患の1例
    古屋 彩, 小泉 祐介, 奥野 貴史, 南口 仁志, 程原 佳子, 安藤 朗, 藤山 佳秀
    滋賀医学 2015年03月
  • 抗体同定に苦慮した自己免疫性溶血性貧血の1症例
    古川 玲奈, 茂籠 弘子, 山下 朋子, 南口 仁志, 小泉 祐介, 程原 佳子
    滋賀医学 2015年03月
  • 発熱性好中球減少症を来たした血液患者10例におけるプレセプシン動態の後方視的解析
    小泉 祐介, 奥野 貴史, 南口 仁志, 藤山 佳秀
    感染症学雑誌 2015年03月
  • 免疫再構築症候群として発症した新規抗酸菌Mycobacterium shigaense感染症の一例
    小泉 祐介, 奥野 貴史, 南口 仁志, 藤山 佳秀
    感染症学雑誌 2015年03月
  • 乳腺原発DLBCLの1例
    南口 仁志, 古屋 彩, 小泉 祐介, 瀬川 秀和, 奥野 貴史, 程原 佳子, 安藤 朗
    臨床血液 2015年01月
  • 当科における原発性脳悪性リンパ腫の治療戦略 自験6症例から学んだこと
    小泉 祐介, 古屋 彩, 奥野 貴史, 南口 仁志, 程原 佳子, 安藤 朗, 藤山 佳秀
    日本エイズ学会誌 2014年11月
  • リツキシマブ時代の当科における骨原発悪性リンパ腫の治療成績
    奥野 貴史, 細羽 桜, 岩佐 磨佐紀, 古屋 彩, 藤城 綾, 小泉 祐介, 瀬川 秀和, 南口 仁志, 程原 佳子, 安藤 朗
    臨床血液 2014年11月
  • 悪性リンパ腫治療後に発症した播種性Mycobacterium avium感染症の1例
    小泉 祐介, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀, 藤城 綾, 古屋 彩
    感染症学雑誌 2014年09月
  • 当院におけるプロカルシトニン(PCT)検査の現状と頻回検査症例の解析 PCTは「CRP化」していないか
    小泉 祐介, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀
    感染症学雑誌 2014年09月
  • 非血縁者間同種骨髄移植を施行したSezary症候群の1例
    南 志乃, 高橋 聡文, 白井 昌江, 藤本 徳毅, 田中 俊宏, 南口 仁志, 程原 佳子
    皮膚の科学 2014年08月
  • 悪性リンパ腫治療後に発症した播種性Mycobacterium avium感染症の一例
    小泉 祐介, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀
    日本化学療法学会雑誌 2014年05月
  • 当院におけるプロカルシトニン(PCT)検査の現状と頻回検査症例の解析 PCTは「CRP化」していないか
    小泉 祐介, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀
    日本化学療法学会雑誌 2014年05月
  • 化学療法中にS.maltophilia肺炎+敗血症を発症したAIDS関連Burkittリンパ腫の1例
    小泉 祐介, 藤城 綾, 古屋 彩, 西村 理恵, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀, 上平 朝子, 白阪 琢磨
    滋賀医学 2014年03月
  • 輸血後感染症検査によって判明した急性C型肝炎の1例
    茂籠 弘子, 山下 朋子, 内林 佐知子, 南口 仁志, 程原 佳子, 湯本 浩史, 古川 玲奈, 塩谷 淳
    滋賀医学 2014年03月
  • 自己末梢血幹細胞移植を施行した心アミロイドーシス症例
    中村 暁子, 奥野 貴史, 古屋 彩, 藤城 綾, 細羽 桜, 小泉 祐介, 瀬川 秀和, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2014年02月
  • 当院における無輸血治療実施の現状
    山下 朋子, 茂籠 弘子, 瀬川 秀和, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2013年08月
  • 縦隔原発精上皮腫、重症再生不良性貧血を合併したダウン症候群成人例
    古屋 彩, 奥野 貴史, 細羽 桜, 瀬川 秀和, 南口 仁志, 程原 佳子, 藤山 佳秀, 石田 光明
    臨床血液 2013年08月
  • 当院における輸血後感染症検査の実施方法とその成績
    茂籠 弘子, 内林 佐知子, 山下 朋子, 湯本 浩史, 瀬川 秀和, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2013年04月
  • Good症候群に重症再生不良性貧血を合併し臍帯血移植を施行した1例
    細羽 桜, 古屋 彩, 瀬川 秀和, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀, 安藤 朗
    滋賀医学 2013年03月
  • 多発性骨髄腫診療におけるボルテゾミブの位置づけ 当院での使用経験から
    瀬川 秀和, 細羽 桜, 古屋 彩, 奥野 貴史, 南口 仁志, 程原 佳子, 安藤 朗, 藤山 佳秀
    日本内科学会雑誌 2013年02月
  • リンパ増殖性疾患が疑われた寒冷凝集素症の1例
    細羽 桜, 瀬川 秀和, 古屋 彩, 奥野 貴史, 南口 仁志, 程原 佳子, 安藤 朗, 藤山 佳秀, 淵田 真一, 島崎 千尋
    臨床血液 2013年02月
  • AIDS関連DLBCLの治療中にPlasmablastic lymphomaを合併し、BD療法を施行した一例
    小泉 祐介, 廣田 和之, 米本 仁史, 大寺 博, 矢嶋 敬史郎, 渡邉 大, 南口 仁志, 西田 泰治, 上平 朝子, 児玉 良典, 大田 泰徳, 藤山 佳秀, 白阪 琢磨
    臨床血液 2012年09月
  • 寒冷凝集素症を合併したびまん性大細胞型B細胞性リンパ腫の1症例
    奥野 貴史, 細羽 桜, 古屋 彩, 瀬川 秀和, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2012年08月
  • Kell系高頻度抗原に対する抗体を保有する妊婦の1例
    茂籠 弘子, 山下 朋子, 内林 佐知子, 湯本 浩史, 山本 梢, 南口 仁志, 程原 佳子, 木村 恵子
    日本輸血細胞治療学会誌 2012年04月
  • 当院でのベンダムスチン使用経験
    浅井 愛, 木藤 克之, 岩佐 磨佐紀, 奥野 貴史, 南口 仁志, 程原 佳子, 藤山 佳秀, 安藤 朗
    滋賀医学 2012年03月
  • びまん性肺胞隔壁型アミロイドーシスの1例
    井上 明星, 新田 哲久, 大谷 秀司, 園田 明永, 高橋 雅士, 村田 喜代史, 南口 仁志, 大澤 真, 向所 賢一
    Japanese Journal of Radiology 2012年02月
  • びまん性大細胞リンパ腫(DLBCL)に合併した寒冷凝集素症の1例
    山下 朋子, 茂籠 弘子, 山本 梢, 内林 佐知子, 湯本 浩史, 奥野 貴史, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2012年02月
  • カプセル内視鏡が治療方針決定に有用であった小腸follicular lymphomaの1症例
    西野 恭平, 辻川 知之, 木藤 克之, 奥野 貴史, 今枝 広丞, 馬場 重樹, 稲富 理, 望月 洋介, 浅井 愛, 岩佐 磨佐紀, 南口 仁志, 齋藤 康晴, 安藤 朗, 程原 佳子, 橋本 真理子, 駒井 康伸, 藤山 佳秀
    栄養-評価と治療 2012年02月
  • 免疫抑制療法後に数種のヘルペスウイルス科ウイルス感染が再活性化した再生不良性貧血の一症例
    岩佐 磨佐紀, 木藤 克之, 浅井 愛, 奥野 貴史, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2012年01月
  • 原発性副腎機能低下症と筋原発悪性リンパ腫を合併したAIDSの一例
    小泉 祐介, 南口 仁志, 木藤 克之, 程原 佳子, 藤山 佳秀
    日本エイズ学会誌 2011年11月
  • 急性前骨髄球性白血病(APL)第3寛解期に非血縁者間同種骨髄移植を施行した症例
    浅井 愛, 奥野 貴史, 岩佐 磨佐紀, 南口 仁志, 木藤 克之, 程原 佳子, 藤山 佳秀, 安藤 朗
    臨床血液 2011年08月
  • 当院における超緊急輸血症例についての解析
    山下 朋子, 茂籠 弘子, 内林 佐知子, 山本 梢, 湯本 浩史, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2011年06月
  • Kell系高頻度抗原に対する抗体による母児血液型不適合の1症例
    茂籠 弘子, 山下 朋子, 内林 佐知子, 湯本 浩史, 南口 仁志, 程原 佳子, 木村 恵子
    日本輸血細胞治療学会誌 2011年03月
  • 同種末梢血幹細胞移植後に合併した類天疱瘡に対してリツキシマブが奏効した悪性リンパ腫症例
    西村 理恵, 木藤 克之, 岩佐 磨佐紀, 浅井 愛, 林 嘉宏, 奥野 貴史, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀, 藤本 徳毅
    臨床血液 2010年09月
  • 心臓・大血管に病変を認める悪性リンパ腫に対する治療
    木藤 克之, 浅井 愛, 岩佐 磨佐紀, 牧野 綾, 古屋 彩, 奥野 貴史, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2010年09月
  • メソトレキセート投与後に発症した慢性活動性EBウイルス感染症の一症例
    奥野 貴史, 浅井 愛, 岩佐 磨佐紀, 南口 仁志, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2010年09月
  • コンピュータクロスマッチによる出庫後の溶血性輸血副作用の調査
    湯本 浩史, 池部 梢, 内林 佐知子, 山下 朋子, 茂籠 弘子, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2010年02月
  • 穿頭ドレナージ、IPM/CS+AMKおよびLZDにて後遺症なく軽快したノカルジア脳・肺・大腿部筋膜下膿瘍の1例
    小泉 祐介, 林 嘉宏, 南口 仁志, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    感染症学雑誌 2009年11月
  • 当院における急性HIV感染症の4症例 血清膠質反応の推移について
    木藤 克之, 牧野 綾, 阪上 彩, 西村 理恵, 林 嘉宏, 奥野 貴史, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2009年09月
  • 稀な臨床経過を認めた2次性急性前骨髄球性白血病の2症例
    阪上 彩, 木藤 克之, 奥野 貴史, 牧野 彩, 西村 理恵, 林 嘉宏, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2009年09月
  • 大腸上皮細胞に対するIL-24の効果
    奥野 貴史, 安藤 朗, 塩谷 淳, 南口 仁志, 木藤 克之, 程原 佳子, 藤山 佳秀
    臨床血液 2009年09月
  • 穿孔・穿通を認める腹部悪性リンパ腫に対する治療
    牧野 綾, 木藤 克之, 阪上 彩, 林 嘉宏, 西村 理恵, 奥野 貴史, 南口 仁志, 安藤 朗, 程原 佳子, 藤山 佳秀, 片山 政伸
    臨床血液 2009年09月
  • Streptococcus equisimilisによる腰椎の慢性化膿性椎体炎に対してMFLX経口投与により長期コントロールが可能であった1例
    小泉 祐介, 林 嘉宏, 南口 仁志, 木藤 克之, 佐々木 雅也, 程原 佳子, 藤山 佳秀
    日本化学療法学会雑誌 2009年04月
  • 穿頭ドレナージ、IPM/CS+AMKおよびLZDにて後遺症なく軽快したノカルジア脳・肺・大腿部筋膜下膿瘍の一例
    小泉 祐介, 林 嘉宏, 南口 仁志, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    感染症学雑誌 2009年03月
  • 交換輸血とγグロブリン投与を行ったABO不適合HDNの1症例
    山下 朋子, 湯本 浩史, 内林 佐知子, 茂篭 弘子, 南口 仁志, 程原 佳子
    日本輸血細胞治療学会誌 2009年02月
  • マウス膵炎モデルにおける膵筋線維芽細胞と骨髄由来間葉系細胞との関係
    橋本 高芳, 安藤 朗, 伴 宏充, 塩谷 淳, 西田 淳史, 西村 貴士, 南口 仁志, 藤山 佳秀
    日本消化器病学会雑誌 2008年09月
  • 造血幹細胞移植後の髄外再発に対し非血縁者間骨髄移植を行った2症例についての検討
    林 嘉宏, 西村 理恵, 小泉 祐介, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2008年09月
  • リンパ増殖性疾患に対する小腸内視鏡(シングルバルーン)の有用性の検討
    木藤 克之, 林 嘉宏, 西村 理恵, 小泉 祐介, 南口 仁志, 北村 憲一, 安藤 朗, 程原 佳子, 辻川 知之, 藤山 佳秀
    臨床血液 2008年09月
  • AIDSに合併した脳原発悪性リンパ腫(PCNSL)の3例
    小泉 祐介, 林 嘉宏, 西村 理恵, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2008年09月
  • プロテアソーム阻害薬(ベルケイド)投与後に播種性帯状疱疹を合併した多発性骨髄腫の1症例
    林 嘉宏, 西村 理恵, 八木 勇紀, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    日本老年医学会雑誌 2008年07月
  • マウス膵炎モデルにおける膵筋線維芽細胞と骨髄由来細胞との関係
    橋本 高芳, 安藤 朗, 伴 宏充, 塩谷 淳, 西田 淳史, 西村 貴士, 南口 仁志, 藤山 佳秀
    日本消化器病学会雑誌 2008年03月
  • CLL患者に生じた単純ヘルペスウィルスによる皮膚潰瘍の1例
    若林 麻記子, 藤本 徳毅, 柴田 史子, 田中 俊宏, 西村 理恵, 南口 仁志
    皮膚の科学 2007年12月
  • Streptococcus mitisによる劇症型感染症にて急激な転帰をとった再生不良性貧血 骨髄移植後症例
    大崎 理英, 妹尾 紅未子, 南口 仁志, 北村 憲一, 木藤 克之, 程原 佳子, 藤山 佳秀, 茂篭 邦彦
    感染症学雑誌 2007年11月
  • マウス膵炎モデルにおける膵間質細胞と骨髄由来細胞との関係
    橋本 高芳, 安藤 朗, 塩谷 淳, 西田 淳史, 西村 貴士, 八木 勇紀, 南口 仁志, 藤山 佳秀
    日本消化器病学会雑誌 2007年09月
  • 最近経験した肺ムコール症 3症例の検討
    木藤 克之, 林 嘉宏, 西村 理恵, 八木 勇紀, 南口 仁志, 北村 憲一, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2007年09月
  • ヒト腸管粘膜におけるIL-32αの発現
    奥野 貴史, 安藤 朗, 南口 仁志, 木藤 克之, 程原 佳子, 藤山 佳秀
    臨床血液 2007年09月
  • 最近経験したAIDS 3症例
    小林 遊, 林 嘉宏, 向井 理恵, 武内 美紀, 瀬川 秀和, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 藤山 佳秀, 程原 佳子
    滋賀医学 2007年03月
  • EBウイルス関連疾患
    内藤 文之, 林 嘉宏, 向井 理恵, 武内 美紀, 瀬川 秀和, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 藤山 佳秀, 程原 佳子
    滋賀医学 2007年03月
  • 原発不明癌の1例
    畑 和憲, 小林 遊, 今枝 広丞, 大崎 理英, 向井 理恵, 妹尾 紅未子, 園田 文乃, 早藤 清行, 峯松 秀樹, 小川 敦弘, 仲原 民夫, 南口 仁志, 北村 憲一, 木藤 克之, 辻川 知之, 安藤 朗, 藤山 佳秀, 佐々木 雅也, 斉藤 康晴, 九嶋 亮治
    滋賀医学 2007年03月
  • この2年間でESDを施行した食道表在癌30例の臨床的検討
    峯松 秀樹, 畑 和憲, 辻川 知之, 小林 遊, 今枝 広丞, 大崎 理英, 向井 理恵, 妹尾 紅未子, 園田 文乃, 早藤 清行, 小川 敦弘, 仲原 民夫, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 藤山 佳秀, 佐々木 雅也, 斉藤 康晴, 九嶋 亮治
    滋賀医学 2007年03月
  • Streptococcus mitisによる劇症型感染症にて急激な転帰をとった再生不良性貧血 骨髄移植後症例
    大崎 理英, 妹尾 紅未子, 南口 仁志, 北村 憲一, 木藤 克之, 程原 佳子, 藤山 佳秀, 茂篭 邦彦
    感染症学雑誌 2007年03月
  • 指状嵌入細胞肉腫の1症例
    林 嘉宏, 向井 理恵, 武内 美紀, 八木 勇紀, 瀬川 秀和, 南口 仁志, 北村 憲一, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀, 山川 光徳
    臨床血液 2006年09月
  • ボリコナゾール投与により末梢神経障害が増悪した急性リンパ性白血病の一例
    瀬川 秀和, 北村 憲一, 林 嘉宏, 向井 理恵, 八木 勇紀, 武内 美紀, 南口 仁志, 木藤 克之, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2006年09月
  • IL-17Fによるヒト大腸筋線維芽細胞からのIL-6の発現誘導 IL-17Aとの効果の比較
    八木 勇紀, 安藤 朗, 稲富 理, 馬場 重樹, 南口 仁志, 北村 憲一, 木藤 克之, 程原 佳子, 藤山 佳秀
    臨床血液 2006年09月
  • Imatinib mesylate投与中に卵巣出血を繰り返した慢性骨髄性白血病;移行期の症例
    木藤 克之, 武内 美紀, 八木 勇紀, 瀬川 秀和, 南口 仁志, 北村 憲一, 安藤 朗, 程原 佳子, 藤山 佳秀
    臨床血液 2006年09月
  • 当院におけるESDの現況 平成16年5月1日より平成17年6月17日で101例を経験して
    峯松 秀樹, 天方 義郎, 柿木 里枝, 馬場 弘道, 瀬川 秀和, 武内 美紀, 卜部 充代, 柳 直子, 妹尾 紅未子, 早藤 清行, 畑 和憲, 南口 仁志, 北村 憲一, 木藤 克之, 辻川 知之, 安藤 朗, 佐々木 雅也, 小山 茂樹, 藤山 佳秀, 斎藤 康晴, 九嶋 亮治
    滋賀医学 2006年03月
  • 膵癌が否定できず手術に至った膵尾部嚢胞の一例
    畑 和憲, 峯松 秀樹, 天方 義郎, 柿木 里枝, 馬場 弘道, 瀬川 秀和, 武内 美紀, 卜部 充代, 柳 直子, 妹尾 紅未子, 早藤 清行, 南口 仁志, 北村 憲一, 木藤 克之, 辻川 知之, 安藤 朗, 佐々木 雅也, 小山 茂樹, 藤山 佳秀, 斎藤 康晴, 九嶋 亮治
    滋賀医学 2006年03月
  • 炎症性腸疾患患者における血小板凝集能の検討
    安藤 朗, 藤野 早苗, 稲富 理, 出口 靖之, 北村 憲一, 南口 仁志, 木藤 克之, 程原 佳子, 藤山 佳秀, 吉田 孝
    日本血液学会・日本臨床血液学会総会プログラム・抄録集 2005年09月
  • 造血幹細胞由来の繊維芽細胞とその前駆細胞
    海老原 康博, 桝屋 正浩, 南口 仁志, 辻 浩一郎, 小川 眞紀雄
    日本血液学会・日本臨床血液学会総会プログラム・抄録集 2005年09月
  • 正常CD34陽性前駆細胞中にWT1遺伝子を白血病細胞と同レベルで発現する細胞が極めて低頻度に存在する
    保仙 直毅, 薗田 精昭, 尾路 祐介, 木村 貴文, 南口 仁志, 玉置 広哉, 川上 学, 村上 雅樹, 藤岡 龍哉, 升田 知機, 金 義浩, 坪井 昭博, 相馬 俊裕, 岡 芳弘, 小川 啓恭, 杉山 治夫
    臨床血液 2002年08月
  • ヒト巨核球系前駆細胞の増殖分化に対するTPO,SCF,SDF-1の制御作用 PI3-K,PKC,MAPKの役割(Action of SDF-1 on proliferation and differentiation of CFU-Meg supported by TPO)
    南口 仁志, 木村 貴文, 藤木 博, 原田 佐智夫, 奥田 恵子, 阿部 達生, 薗田 精昭
    International Journal of Hematology 2001年03月
  • Simultaneous activation of signals through c-MPL, c-KIT, and CXCR4 dramatically enhances proliferation and differentiation of CFU-MEG: Possible ROLE of PI3-K, PKC, and mapk pathways
    H. Minamiguchi, T. Kimura, H. Fujiki, S. Harada, J. Wang, K. Okuda, H. Miyazaki, T. Bamba, T. Abe, Y. Sonoda
    Blood 2000年12月
    The a-chemokine receptor CXCR4 is expressed on peripheral blood (PB)-derived CD34+ cells. We sorted PBCD34+IL-6R cells, most of which expressed high level of c-kit receptor, and studied the effect of stromal cell-derived factor-1 (SDF-1) on proliferation and differentiation of human megakaryocytic progenitor cells (CFU-Meg) in the presence or absence of stem cell factor (SCF) and/or thrombopoietin (TPO). TPO alone induced significant number of CFU-Meg colonies. However, SDF-1 or SCF alone did not support CFU-Meg colony formation. SDF-1 and SCF respectively showed additive effect on CFU-Meg colony formation in the presence of TPO. Interestingly, a combination of SDF1, SCF, and TPO dramatically induced twice more CFU-Meg colonies supported by TPO alone. This synergistic effect was more evident when PBCD341L-6R c-kit1™ cells were used as the target. This distinct synergistic effect of the three different signals was confirmed by single cell-clone sorting experiments. Neutralizing antibody to CXCR4 or ckit abrogated the additive effect on CFU-Meg colony formation supported by the relevant factor. In the presence of neutralizing antibody for c-mpl, CFU-Meg colony formation supported by three signals was completely suppressed, suggesting the essential role of signaling through c-mpl in this unique synergistic action. Moreover, the mean ploidy of megakaryocytes was 10.32+6.41 N in the presence of three signals, which was significantly higher than that (8.11±4.10N) of TPO alone. In order to elucidate the mechanism of this synergistic action, we examined the effects of various kinase inhibitors on CFU-Meg colony formation. LY294002 and GF109203X, inhibitors of PI3-K and PKC, completely or partially inhibited this synergistic action. In contrast, MEK inhibitor (PD98059), did not affect proliferation of CFU-Meg, suggesting that the MAPK plays an important role in maturation of CFU-Meg. These results provide an evidence that simultaneous activation of the three signals through c-mpl, c-kit, and CXCR4 can induce in vitro proliferation and differentiation of CFU-Meg, and that SDF-1 functions as one of Meg-POTs.
  • ヒトIL-9の巨核球造血促進(Meg-POT)作用 SCF,Epoとの相乗効果について
    藤木 博, 木村 貴文, 南口 仁志, 奥田 恵子, 阿部 達生, 園田 精昭
    臨床血液 2000年10月
  • IL-6R/IL-6融合蛋白質(Fusion protein,FP)を用いる末梢血由来造血前駆細胞のex vivo増幅
    王 剣鋒, 木村 貴文, 南口 仁志, 藤木 博, 原田 佐智夫, 奥田 恵子, 保川 清, 阿部 達生, 薗田 精昭
    International Journal of Hematology 2000年04月
  • IL-11によるAML細胞(L-CFU)の長期培養下クローン性増殖の制御
    木村 貴文, 南口 仁志, 藤木 博, 奥田 恵子, 阿部 達生, 薗田 精昭, 兼子 裕人, 横田 昇平, 中川 均, 藤井 浩
    臨床血液 1999年09月
  • 純化造血幹細胞分画におけるテロメラーゼ活性とLTC-IC,extended LTC-ICの相関
    南口 仁志, 坂部 秀明, 藤木 博, 木村 貴文, 八幡 尚之, 大屋敷 一馬, 大屋敷 純子, 外山 圭助, 奥田 恵子, 阿部 達生
    International Journal of Hematology 1999年04月
  • gp130を介するシグナルを用いた末梢血由来造血前駆細胞のex vivo増幅
    木村 貴文, 南口 仁志, 阿部 達生, 薗田 精昭, 藤木 博, 坂部 秀明
    臨床血液 1998年10月

MISC

  • 同種骨髄移植を施行したSezary症候群の1例
    南 志乃, 高橋 聡文, 白井 昌江, 加藤 威, 藤本 徳毅, 中西 健史, 南口 仁志, 田中 俊宏
    臨床皮膚科 69(11) 853-858 2015年10月
    60歳代,男性.湿疹として加療を受けていたが改善を認めず,紅皮症となったため当院を紹介されて受診した.初診時の皮膚生検の病理組織検査では異型性は乏しかったが,末梢血のフローサイトメトリーを施行したところCD4陽性CD7陰性細胞の増加を認めたことから,異常なT細胞の増殖を疑った.末梢血と皮膚組織のサザンブロット法による遺伝子再構成検査を施行したところ,TCRCβ領域とJγ領域の再構成バンドを認めたため,Sezary症候群と診断した.局所療法と化学療法を含めた複数の治療に抵抗性で,本人の希望もあったことから,同種骨髄移植を施行した.しかし,経過中に肺炎を発症して敗血症から多臓器不全に至り,移植24日目に死亡した.移植を行う場合,効果の高い前処置の選択や移植前の治療反応性から適応を判断することが重要であると考えるが,Sezary症候群の移植症例は少なく,今後の症例集積が待たれる.(著者抄録)
  • 私のこの一枚 EBV-positive systemic T-cell lymphoproliferative disease of childhoodの成人女性症例
    程原 佳子, 木藤 克之, 岩佐 磨佐紀, 浅井 愛, 奥野 貴史, 南口 仁志, 藤山 佳秀, 石田 光明
    血液フロンティア 22(4) 471-476 2012年03月